One class of medications gaining popularity for their role in treating obesity and type 2 diabetes is GLP-1 receptor agonists (GLP-1RAs), which mimic the action of the naturally occurring incretin hormone GLP-1. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.